SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-015255
Filing Date
2023-08-24
Accepted
2023-08-24 16:15:13
Documents
12
Period of Report
2023-08-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K nrbo-20230823x8k.htm   iXBRL 8-K 37309
  Complete submission text file 0001558370-23-015255.txt   157942

Data Files

Seq Description Document Type Size
2 EX-101.SCH nrbo-20230823.xsd EX-101.SCH 3147
3 EX-101.LAB nrbo-20230823_lab.xml EX-101.LAB 15927
4 EX-101.PRE nrbo-20230823_pre.xml EX-101.PRE 10070
6 EXTRACTED XBRL INSTANCE DOCUMENT nrbo-20230823x8k_htm.xml XML 4873
Mailing Address 200 BERKELEY ST. FL 19 BOSTON MA 02116
Business Address 200 BERKELEY ST. FL 19 BOSTON MA 02116 (857) 702-9600
NeuroBo Pharmaceuticals, Inc. (Filer) CIK: 0001638287 (see all company filings)

IRS No.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37809 | Film No.: 231202354
SIC: 2834 Pharmaceutical Preparations